05 ☨ Statistically

different between Spring 2009 and Spring 2010 at p < .05 P20 LACK OF OSTEOPOROSIS TREATMENT IN REAL WORLD HIP FRACTURE GM6001 price patients Kelly Krohn, MD, Lilly USA, Indianapolis, IN PURPOSE: National Osteoporosis Foundation guidelines recommend that postmenopausal individuals age 50 and older presenting with hip fracture should be considered for treatment Ferrostatin-1 supplier with pharmacologic osteoporosis (OP) treatment. This study examined patterns of OP treatment strategies among hip fracture (HFx) patients in real world clinical practice. METHODS: Patients aged 50+ with an HFx between 1/1/2002 and 12/31/2010 (first observed HFx = index) were identified from a large U.S. administrative claims database. Patients included for study had 6+ months of pre-index continuous enrollment (baseline), no baseline evidence of teriparatide (TPTD), cancer, or Paget’s disease. Patients were followed for up-to 36 months post-index to observe patterns in pharmacologic OP treatment strategies. Five cohorts were constructed based on pre- and post-index use of OP treatment: patients with no observed evidence of OP treatment pre- or post-index (N/N); new bisphosphonate (BP)

initiators with no baseline BP (N/BP); BP continuers with baseline BP (BP/BP); new TPTD initiators with no baseline BP treatment (N/TPTD); TPTD initiators switching from prior BP (BP/TPTD). Demographics, clinical characteristics, BAY 11-7082 nmr and healthcare resource use were compared across the 5 cohorts. RESULTS: Study included 71,115 patients. The majority of the sample, 53,634 (75 % of total) patients, was

observed to have no OP treatment (N/N) over a median of 352 days of follow-up; 26,238 of whom had ≥1 year of follow-up. New BP initiators (N/BP; 9,187 patients) started BP treatment within a median of 117 days. BP continuers (BP/BP; 7,463 patients) resumed treatment within a median of 58 days. New TPTD initiators (N/TPTD; 346 patients) started TPTD treatment within a median of 138 days. TPTD initiators switching from prior BP (BP/TPTD; 485 patients) switched to TPTD treatment within a median of 64 days. Sclareol Mean ages ranged from 74.0 (BP/TPTD) to 80.5 (N/N) years. The N/N cohort was the oldest (81 vs. 74–79 years), had the highest proportion of males (39 % vs. 8–18 %), and the lowest baseline use rates of systemic glucocorticoids (13 % vs. 17–30 %) and dual energy X-ray absorptiometry scans (2 % vs. 5–17 %). CONCLUSIONS: In spite of a sentinel event of a hip fracture, which is a known risk factor for future fracture, 75 % of patients had no evidence of OP treatment over a median follow-up of 352 days. These data provide further evidence of a substantial gap in the management of OP among patients at very high risk for fractures.